CLIMATE
Biosimilar Cetuximab Antibody
About
Cetuximab, a biosimilar developed entirely in Turkey by TÜBİTAK MAM Biotechnology AG, is an IgG1 monoclonal antibody targeting the EGFR (HER1) receptor. During product design, protein structure, binding affinity and ADCC function were optimized to biosimulate the reference product.
In EGFR positive tumor models, especially colorectal cancer;
* Cell proliferation,
* Signaling pathway suppression,
* It is a reliable research tool for antibody-mediated cytotoxicity assays.
Product Overview
Biotechnological drug produced as a biosimilar of the antibody cetuximab.
Product Name
Biosimilar-Cetuximab Antibody
Product Short/Code Name
Biosimilar-Cetuximab
Product Type
Prototype Product
Areas of Use
Preclinical cancer research,
Anti-angiogenic therapy response analyses,
Target receptor function validations,
Cell-based biological activity assays.
Developer Research Groups
Biotechnology Research Group
Production and Technology Status
Technology Readiness Level (THS)
THS 4
Technical Specifications
Biosimilar of Cetuximab
Recombinant Full Antibody
Owned Standard
GMP Standard
